New Tests for Assessing Non-Inferiority and Equivalence from Survival Data

Kallappa M. Koti^{*}

Show more

References

[1] “E-10: Guidance on Choice of Control Group in Clinical Trials,” International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), Vol. 64, No. 185, 2000, pp. 51767-51780.

[2] R. B. D’Agostino, J. M. Massaro and L. M. Sullivan, “Non-Inferiority Trials: Design Concepts and Issues— The Encounters of Academic Consultants in Statistics,” Statistics in Medicine, Vol. 22, No. 2, 2003, pp. 169-186.
doi:10.1002/sim.1425

[3] G. G. Koch, “Non-Inferiority in Confirmatory Active Control Clinical Trials: Concepts and Statistical Methods,” American Statistical Association: FDA/Industry Workshop, Washington, D.C., 2004.

[4] S. Wellek, “Testing Statistical Hypothesis of Equivalence,” CHAPMAN & HALL/CRC, New York, 2003.

[5] B. Efron, “Censored Data and the Bootstrap,” Journal of the American Statistical Association, Vol. 76, No. 374, 1981, pp. 312-319.
doi:10.1080/01621459.1981.10477650

[6] R. Simon, “Confidence Intervals for Reporting Results of Clinical Trials,” Annals of Internal Medicine, Vol. 105, No. 3, 1986, pp. 429-435.

[7] L. Rubinstein, M. Gail and T. Santner, “Planning the Duration of a Comparative Clinical Trial with Loss to Follow-Up and a Period of Continued Observation,” Journal of Chronic Disease, Vol. 34, No. 9-10, 1981, pp. 469-479. doi:10.1016/0021-9681(81)90007-2

[8] D. R. Bristol, “Planning Survival Studies to Compare a Treatment to an Active Control,” Journal of Biopharma ceutical Statistics, Vol. 3, No. 2, 1993, pp. 153-158.
doi:10.1080/10543409308835056

[9] R. L. Berger and J. C. Hsu, “Bioequivalence Trials, Inter section-Union Tests and Equivalence Confidence Sets,” Statistical Science, Vol. 11, No. 4, 1996, pp. 283-319.
doi:10.1214/ss/1032280304

[10] D. Hauschke and L. A. Hothorn, “Letter to the Editor,” Statistics in Medicine, Vol. 26, No. 1, 2007, pp. 230-236.
doi:10.1002/sim.2665

[11] SAS Institute Inc., “SAS/STAT User’s Guide,” Version 8, Cary, 2000.

[12] R. Brookmeyer and J. Crowley, “A Confidence Interval for the Median Survival Time,” Biometrics, Vol. 38, No. 1, 1982, pp. 29-41. doi:10.2307/2530286

[13] D. Collett, “Modeling Survival Data in Medical Research,” 1st Edition, Chapman & Hall, London, 1994.

[14] N. Reid, “Estimating the Median Survival Time,” Bio metrika, Vol. 68, No. 3, 1981, pp. 601-608.
doi:10.1093/biomet/68.3.601

[15] G. J. Babu, “A Note on Bootstrapping the Variance of Sample Quantiles,” Annals of the Institute of Statistical Mathematics, Vol. 38, 1985, pp. 439-443.
doi:10.1007/BF02482530

[16] The University of Texas at Austin, “Setting and Resam pling in SAS,” 1996.
http://ftp.sas.com/techsup/download/stat/jackboot.htm/

[17] K. M. Keaney and L. J. Wei, “Interim Analyses Based on Median Survival Times,” Biometrika, Vol. 81, No. 2, 1994, pp. 279-286. doi:10.1093/biomet/81.2.279

[18] E. C. Fieller, “The Distribution of the Index in a Normal Bivariate Population,” Biometrika, Vol. 24, No. 3-4, 1932, pp. 428-440. doi:10.1093/biomet/24.3-4.428

[19] D. V. Hinkley, “On the Ratio of Two Correlated Normal Variables,” Biometrika, Vol. 56, No. 3, 1969, pp. 635-639. doi:10.1093/biomet/56.3.635

[20] K. M. Koti, “Use of the Fieller-Hinkley Distribution of the Ratio of Random Variables in Testing for Non-Inferiority and Equivalence,” Journal of Biopharmaceutical Statistics, Vol. 17, No. 2, 2007, pp. 215-228.
doi:10.1080/10543400601177335

[21] K. M. Koti, “New Tests for Null Hypothesis of Non Unity Ratio of Proportions,” Journal of Biopharmaceuti cal Statistics, Vol. 17, No. 2, 2007, pp. 229-245.
doi:10.1080/10543400601177426

[22] B. Efron and R. J. Tibshirani, “An Introduction to the Bootstrap,” Chapman & Hall, New York, 1993.

[23] M. E. Stokes, C. S. Davis and G. G. Koch, “Categorical Data Analysis Using the SAS System,” SAS Institute Inc., Cary, 1995.